Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2025)

Genmab A has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $95.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 41.79% year-over-year to $95.0 million; the trailing twelve-month figure through Dec 2025 stood at $95.0 million (up 41.79% YoY), and the FY2025 full-year result was $95.0 million, up 41.79% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $95.0 million, up from $67.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $95.0 million in Q4 2025, with the low at $67.0 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $77.7 million across 3 years, with a median of $71.0 million in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue retreated 5.63% — and 2025, when it surged 41.79%.
• Genmab A's Non-Current Deffered Revenue stood at $71.0 million in 2023, then slipped by 5.63% to $67.0 million in 2024, then soared by 41.79% to $95.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $95.0 million (Q4 2025), $67.0 million (Q4 2024), and $71.0 million (Q4 2023), per Business Quant data.